In the deal, Cantel said it will pay $7 million upfront with an additional $3.5 million to be paid based on performance-based milestones over a two-year period, the Little Falls, N.J.-based company said.
“We’re excited that Vista Research Group is now part of Cantel. The integration of their water treatment technologies into our existing portfolio allows us to offer our customers more comprehensive infection prevention solutions that provide clean water across all touchpoints in the dental clinic. This acquisition also reinforces our position as the market leader in dental water compliance,” Vista Research Group prez & CEO Jorgen Hansen said in a press release.
Ashland, Ohio-based Vista Research Group reported sales of approximately $2 million during the previous fiscal year. The company currently has a portfolio of solutions for filtration, purification, treatment and management of dental water to reduce infection risk, improve workflows and patient care and protect dental equipment.
“The addition of Vista Research Group’s solutions will broaden our dental water purification portfolio and advance the development of our product line. In addition to our DentaPure Cartridge, it also will enable us to provide a full suite of end-to-end dental water compliance solutions to dental practices. In our ongoing commitment to infection prevention and compliance, we look forward to driving the awareness of and access to the VistaPure, VistaCool, and VistaClear products so more dental practices can benefit from improved efficiency, simplified workflows, and better protection for both patients and staff,” Cantel dental division prez Gary Steinberg said in a prepared statement.
Last November, Cantel Medical posted fiscal first-quarter earnings that matched the consensus forecast on Wall Street, but missed the mark with its top-line numbers.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.